Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CTPS1 | P17812 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.34 |
| ▸ | PTGES | O14684 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | IDE | P14735 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917384 | 0.91 | CYP1A2 (0.39) | GPR55IDH1CTPS1CYP1A2CYP3A4 | |
| SCHEMBL14554943 | 0.89 | GPR55 (0.39) | GPR55IDH1CTPS1CYP1A2CYP3A4 | |
| SCHEMBL14555000 | 0.75 | GPR55 (0.68) | GPR55IDH1 | |
| SCHEMBL15918304 | 0.75 | GPR55 (0.68) | GPR55IDH1 | |
| SCHEMBL15918468 | 0.73 | GPR55 (0.48) | GPR55IDH1CTPS1 | |
| SCHEMBL15917525 | 0.71 | TRPV3 (0.53) | GPR55IDH1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14554991 | 0.71 | TRPV3 (0.53) | GPR55IDH1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15935058 | 0.71 | GPR55 (0.47) | GPR55IDH1CTPS1CYP1A2CYP3A4 | |
| SCHEMBL15917921 | 0.71 | PTK2 (0.47) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14554948 | 0.71 | GPR55 (0.47) | GPR55IDH1CTPS1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729459-B1 | SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-9199962-B2 | Substituted azaheterocycles for the treatment of cancer | MERCK PATENT GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199962-B2 | Substituted azaheterocycles for the treatment of cancer | MERCK PATENT GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221366-A1 | Substituted Azaheterocycles for the Treatment of Cancer | CCNH, CCNA1, MYC | GPR55 2224/4885IDH1 324/4885CTPS1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.